Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for pridopidine as a treatment for Huntington’s disease (HD). An MAA is submitted to seek approval to market a medicine in European Union member countries. The MAA review process typically takes 12-14 months and if approved, pridopidine could be prescribed to first HD patients in Europe by the end of 2025.

The International Huntington Association is “hopeful that we get closer to a cure for Huntington’s Disease and is keen on all the research developments that are happening in the community”.

Read the press release

Read the community letter